Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Alimera Sciences, Inc. (NASDAQ: ALIM) is a leading global pharmaceutical company committed to advancing retinal health. Founded in June 2003, the company specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Alimera's primary focus is on diseases affecting the retina, particularly those that are not well managed by current therapies. The company's flagship product, ILUVIEN, is a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) outside the U.S.
ILUVIEN utilizes CONTINUOUS MICRODOSING™ technology, releasing sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months. This technology helps to reduce disease recurrence, thereby enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S. and multiple international markets, including 17 European countries, China, and regions in the Middle East.
Recently, Alimera announced positive data from several clinical studies, such as the PALADIN study, which evaluated the long-term safety of ILUVIEN in treating DME. The company also made headlines by completing enrollment for the Synchronicity Study, focusing on YUTIQ, another fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
Moreover, Alimera continues to expand its executive team to strengthen its financial and operational capabilities. Elliot Maltz, C.P.A., has been named as the new Chief Financial Officer to drive growth and improve cash flow. The company's European operations are managed through its subsidiary, Alimera Sciences Limited, based in London.
Financially, Alimera Sciences has shown robust growth. In Q4 2023, the company reported net revenues of $26.3 million, an 88% increase compared to the same period in 2022. For the full year 2023, net revenues were up 49% to $80.8 million. This growth is a testament to the successful commercialization of ILUVIEN and YUTIQ.
Looking ahead, Alimera aims to further its mission of being invaluable to patients, physicians, and partners concerned with retinal health. The company is actively involved in numerous clinical studies and regulatory efforts to expand the therapeutic indications for its products, ensuring continued innovation and improved patient outcomes.
For more information, please visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) announced that data from its ILUVIEN studies will be presented during the annual ARVO conference in New Orleans from April 23-27, 2023. Four posters will highlight findings from the PALADIN study, which focused on the long-term outcomes in eyes requiring IOP lowering surgery after treatment with the 0.19 mg Fluocinolone Acetonide Implant for DME. The PALADIN study, a 36-month observational study involving 202 eyes across 41 sites, confirmed the benefits of corticosteroid use in preventing uncontrolled IOP elevation, while also showing improvement in vision and reduction in treatment burdens. Although ARVO is a significant event in ophthalmology, it does not endorse any products presented.
Alimera Sciences has expanded its partnership with Horus Pharma to market ILUVIEN more broadly in the Nordic countries: Denmark, Finland, Norway, and Sweden. This collaboration aims to enhance commercial efforts for treating conditions like diabetic macular edema (DME) and non-infectious uveitis. Rick Eiswirth, CEO of Alimera, expressed confidence in Horus's capabilities to leverage their expertise in these new markets. Horus's CEO, Claude Claret, noted the potential for long-acting therapies to benefit healthcare systems. ILUVIEN is already approved in several regions for various indications and offers sustained release therapy.
Alimera Sciences, Inc. (Nasdaq: ALIM) reported a 13% increase in 2022 product revenue to $54.1 million, driven by a 22% growth in global end user demand, totaling 9,266 units. The U.S. segment grew 23%, while the international segment rose 21%. However, international net revenue dropped 38% to $19.9 million due to unfavorable foreign exchange rates. Operating expenses increased 11% to $57.8 million as the company invested in growth post-pandemic. Alimera also repurchased Series A Preferred Stock, alleviating a $24 million liquidation preference, and amended a $45 million term loan to extend the interest-only period.
FAQ
What is the current stock price of Alimera Sciences (ALIM)?
What is the market cap of Alimera Sciences (ALIM)?
What is Alimera Sciences, Inc. specialized in?
What is ILUVIEN?
Where is Alimera Sciences headquartered?
What are the latest financial results for Alimera Sciences?
Who is the new Chief Financial Officer of Alimera Sciences?
What recent clinical studies has Alimera Sciences completed?
In which regions is ILUVIEN approved?
What is the mission of Alimera Sciences?
What technology does ILUVIEN utilize?
Where can I find more information about Alimera Sciences?
